Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
CEO: Daniel Bendheim. Company website
Phibro Animal Health Corporation (PAHC) trades at $34.56, up 0.32% on the day, as of Sep 20, 2026 14:59 UTC.
Phibro Animal Health Corporation has a market capitalisation of $1.40B, calculated from the live PAHC share price and shares outstanding.
PAHC trades at a trailing P/E of 14.16, from earnings per share of $2.44 over the last twelve months.
Phibro Animal Health Corporation generated revenue of $1.52B over the trailing twelve months, which puts the stock at 0.92 times sales.
Yes. Phibro Animal Health Corporation pays a dividend yielding 1.21% on the current share price.
PAHC has traded between $28.25 and $60.08 over the past 52 weeks, and the last price is 42.5% below that high.
Yes. Phibro Animal Health Corporation keeps 6.57% of revenue as net income over the trailing twelve months.
Wall Street analysts rate PAHC Buy, with an average price target of $28.00, 19.0% below the current price.
Phibro Animal Health Corporation is classified under the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is domiciled in US.
Daniel Bendheim is the chief executive of Phibro Animal Health Corporation, which employs 2,605 people.
QFI Terminal shows PAHC with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PAHC in Terminal See plans